some machine learning algorithms for sex identification based on linear mandibular measurements derived from CT scans .
İtriyum-90 (Y90) radyoembolizasyonu primer ve metastatik karaciğer kanseri tedavisinde kullanılan bir yöntemdir. Tedavide, Y90 aktivite miktarının (MBq) hastaya spesifik dozimetri ile hesaplanması gerekmektedir. Her bir hasta için dozimetrinin yapılması oldukça uzun sürmektedir. Klinikteki işleyişi hızlandırmak, kanser hastalarına daha hızlı tedavi sağlamak ve ilgili personelin iş yükünü azaltarak efektif çalışma düzeni oluşturmak adına dozimetrinin yerini alabilecek bir alternatife ihtiyaç duyulmaktadır. Bu nedenle çalışmada, Y90 radyoembolizasyonu için hesaplanmış dozimetri sonuçları kullanılarak üç farklı makine öğrenmesi regresyon metodu modellenmesi sonucu Y90 terapötik aktivite miktarının tahmin edilmesi amaçlanmıştır. Tümör kütlesi (g), karaciğer kütlesi (g), tümör / karaciğer sayım oranı (%), şant oranı (%), tümör tutulumu ve karaciğer tutulumu gibi nümerik parametreler girdi olarak, Y90 aktivite miktarı (MBq) çıktı olarak belirlenmiştir. Çoklu doğrusal regresyon (ÇDR), rassal orman regresyonu (ROR) ve destek vektör regresyonu (SVM) kullanılarak tahminler gerçekleştirilmiştir. Tahmin yöntemlerinin performanslarını değerlendirmede ortalama mutlak yüzde hatası (MAPE), ortalama mutlak hata (MAE), ortalama karekök sapması (RMSE), ortalama karesel hata (MSE) ve doğruluk (%) ölçütleri kullanılarak optimal tahmin modeli belirlenmeye çalışılmıştır.
Introduction: F18 and Ga68 radioisotopes are used in PET imaging for prostate cancer. It was aimed to calculate the prostate, testicle and bladder effective doses (ED) caused by F18 and Ga68 used in prostate cancer imaging with PET/CT via simulation with the GATE toolkit and evaluate the ED in terms of fertility. Methods: The prostate, testicle and bladder were defined together with their geometric properties and densities in GATE simulation. F18 and Ga68 with activity of 277.5 MBq and 151.7 MBq were identified in the prostate as a source organ. The ED, uncertainties, and S values were taken as an output file in the TXT format with the DoseActors command. S values were used for validation of the simulation. Results: The ED of the prostate, total testicle and bladder for F18 were found to be 6.627E-041.799E-06, 12.74E-074.11E-08 and 1.617E-054.317E-09 (Gy/s), respectively. The ED of the prostate, total testicle, and bladder for Ga68 were found to be 9.195E-042.660E-06, 6.54E-072.93E-08 and 4.290E-056.936E-09 (Gy/s), respectively. Conclusions: It was found that Ga68 produced high prostate and bladder ED, and F18 produced high testicular ED. In terms of male fertility, Ga68 seems to be a good alternative because it produces low testicular doses. The ED of the testicle both F18 and Ga68 were below the reported spermatogonia and azoospermia dose.
aims: It was aimed to determine the amount of radiation dose rate emitted from the patients who underwent imaging with low activity at the new generation PET/CT device. In addition, it was aimed to examine the relationship between biological and physical excretion by measuring the activity amounts in urine and sweat samples with a well-type counter, as well as dose rates measured from various parts of the body with the Geiger Muller counter (GM). This study also aimed to reorganize the clinical conditions by evaluating the dose rates in terms of radiation safety and comparing the results with national and international regulations. background: New generation PET/CT devices provide quality images using low radiopharmaceutical activities. Dose monitoring is carried out for nuclear medicine personnel, other health personnel, and companions by determining the radiation dose emitted from low-activity patients to the environment. In particular, it is necessary to revise the working conditions of the personnel according to the radiation dose exposed. objective: It was aimed to reevaluate the radiation dose rate transmitted to the environment from patients injected with FDG. method: A total of 31 patients (14F, 17M) who underwent 18F-FDG PET/CT imaging were included. The mean 18F-FDG activity of 7.26±1.29 mCi was used for injection. After injection, radiation dose rates (mR/h) were measured at distances of 25, 50, 100, 150, and 200cm for 3 different periods from the level of the head, thorax, abdomen, and pelvis by using a GM counter. Additionally, biological samples such as urine and sweat were taken during 3 different periods. The activity amounts(µCi) in the samples were measured with a well-type counter. result: Strong correlations were calculated between normalized dose rates obtained by all regions and time. Considering the nuclear medicine staff handling time with a PET/CT patient, the average dose received by staff was calculated between a range of 0.002-0.004mSv/pt. The radiation dose exposed to the porter and nurse was calculated as 0.049mSv/pt for the 2nd hour and 0.001-0.007mSv/pt for the 4th hour, respectively. The companion was exposed to a dose between 0.073-0.147mSv and 0.024-0.048mSv for public transport and private car transportation after 4-6 hours of injection (for 30-60 min of travel duration), respectively. For inpatients, the received dose for porters, serving 20min from a distance of 30cm for the 2nd and 4th hours after PET/CT scan, was 0.049 mSv/pt and 0.048 mSv/pt, respectively. And for nurses serving from 50cm distance between 1-5 minutes, these values were found to be 0.001-0.007mSv/pt, 0.001-0.007mSv/pt, and 0.001-0.006mSv/pt, respectively. conclusion: The radiation dose of nuclear medicine staff, porters, nurses, and companions are found to be below the recommended dose limit by the ICRP. According to our results, there is no need for any restrictions for patients, companions, or healthcare personnel in PET/CT units. other: None
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.